UBI® FMDV NS ELISA (CATTLE)

DIRECTION INSERT
PUBLICATION ON UBI® FMDV NS ELISA (CATTLE)

Foot-and-Mouth Disease (FMD) caused by the Foot-and-Mouth Disease Virus (FMDV) is the most economically significant disease of domestic livestock.

In response to 1997/99 outbreak of FMD in swine and cattle in Taiwan, UBI has developed a series of highly specific peptide-based diagnostic tests capable of detecting FMDV infection, and uniquely capable of differentiating FMD-vaccinated from infected animals. This gave UBI a competitive advantage in confronting the full-blown FMD pandemic that emerged in 2001.
The UBI FMDV differential diagnostics represent a tremendous advance to the management of FMD outbreaks, and will provide significant economic benefit to the agricultural industry of Taiwan and other areas of the world now enduring FMD outbreaks. The Office International des Epizooties (OIE), the international organization that works with the UN's FAO agency to control FMDV, recommends the use of differential diagnostics as a tool for monitoring FMDV and for establishment of FMDV-free status. UBI now produces, the UBI® FMDV ELISAs. These are the best user-friendly commercial scale tests in the world that detect FMDV infection and differentiate vaccinated from infected animals.

UBI is working with the Council of Agriculture of Taiwan and the United States Department of Agriculture for registration of the UBI® FMDV ELISA diagnostics. The UBI FMDV tests are in successful trials under auspices of the FAO/Int'l Atomic Energy Agency, and other registration efforts are underway in the EU and with the Office International des Epizooties. The tests have been registered in SPAIN in collaboration with our partner Ingenasa. An unprecedented relaxation of the guidelines that restricted the export of vaccinated animals was issued by the Office International des Epizooties in May 2002, in response to the new technical developments in FMD control. The new rules are expected to result in more widespread use of our FMD diagnostics.

UBI® FMDV VP1 ELISA (CATTLE)

DIRECTION INSERT
ORDERING CONTACT

Foot-and-Mouth Disease (FMD) caused by the Foot-and-Mouth Disease Virus (FMDV) is the most economically significant disease of domestic livestock. Conservative estimates for the worldwide markets for FMD diagnostics range from US$10-$50 millions, and are based on different models of the percentage of swine and ruminants which would be screened by such diagnostics.

In response to the 1997/99 outbreak of FMD in swine and cattle in Taiwan, UBI has developed a series of highly specific peptide-based diagnostic tests capable of detecting FMDV infection, and uniquely capable of differentiating FMD-vaccinated from infected animals. This gave UBI a competitive advantage in confronting the full-blown FMD pandemic that emerged in 2001.

The UBI FMDV differential diagnostics represent a tremendous advance to the management of FMD outbreaks, and will provide significant economic benefit to the agricultural industry of Taiwan and other areas of the world now enduring FMD outbreaks. The Office International des Epizooties (OIE), the international organization that works with the UN's FAO agency to control FMDV, recommends the use of differential diagnostics as a tool for monitoring FMDV and for establishment of FMDV-free status. UBI now produces, the UBI® FMDV ELISAs. These are the best user-friendly commercial scale tests in the world that detect FMDV infection and differentiate vaccinated from infected animals.

The UBI® FMDV VP1 ELISA (CATTLE) is an investigatory test. It is a qualitative enzyme-linked immunosorbent assay (ELISA) for in vitro detection of antibodies to Foot-and-Mouth Disease Virus (FMDV) in vaccinated or infected cattle. It is a test for the serological surveillance of antibodies to FMDV that result from either vaccination or the presence of infectious FMDV. The UBI® FMDV VP1 ELISA may be used to evaluate vaccinee status when used in combination with the UBI® FMDV NONSTRUCTURAL PROTEIN ELISA (CATTLE) to distinguish antibodies evoked by FMDV vaccination from antibodies evoked by current or previous FMDV infection.